(Q37600496)

English

Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials

scientific article published on 18 September 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

0 references

1 reference

Europe PubMed Central

Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

0 references

0 references

systematic review

1 reference

based on heuristic

inferred from title

Toni K Choueiri

3

object named as

Toni K Choueiri

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

author name string

Youjin Je

1

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Fabio A B Schutz

2

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

publication date

18 September 2009

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

967-974

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

Anti-angiogenesis: new concept for therapy of solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of adverse effects of anti-VEGF therapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The biology of VEGF and its receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Hemostatic complications of angiogenesis inhibitors in cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Severe epistaxis with tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

CONSORT for reporting randomised trials in journal and conference abstracts

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of sorafenib in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of sunitinib in patients with advanced neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of sorafenib in advanced thyroid cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Operating characteristics of a rank correlation test for publication bias

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeted therapy for metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab, bleeding, thrombosis, and warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

What is the risk of intracranial bleeding during anti-VEGF therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970222-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(09)70222-0

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37600496&oldid=2128439389"